Evidence map›Paper›PMID 36291035›Full record

ReviewBiosensors2022

Advances in Biosensing Technologies for Diagnosis of COVID-19.

Sulaiman Alsalameh, Khalid Alnajjar, Tariq Makhzoum, Noor Al Eman, Ismail Shakir, Tanveer Ahmad Mir, Khaled Alkattan, Raja Chinnappan, Ahmed Yaqinuddin

Open access · goldAbstract readReview
In one paragraph

Review in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sulaiman AlsalamehCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Khalid AlnajjarCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0000-0002-2930-6893
Tariq MakhzoumCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Noor Al EmanCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Ismail ShakirCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0000-0002-8026-9549
Tanveer Ahmad MirLaboratory of Tissue/Organ Bioengineering and BioMEMS, Organ Transplant Centre of Excellence, Transplant Research and Innovation Department, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
Khaled AlkattanCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0000-0002-1372-9883
Raja ChinnappanCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0000-0002-2288-4287
Ahmed YaqinuddinCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.ORCID 0000-0001-7536-910X
Alfaisal University · SAKing Faisal Specialist Hospital & Research Centre · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has severely impacted normal human life worldwide. Due to its rapid community spread and high mortality statistics, the development of prompt diagnostic tests for a massive number of samples is essential. Currently used traditional methods are often expensive, time-consuming, laboratory-based, and unable to handle a large number of specimens in resource-limited settings. Because of its high contagiousness, efficient identification of SARS-CoV-2 carriers is crucial. As the advantages of adopting biosensors for efficient diagnosis of COVID-19 increase, this narrative review summarizes the recent advances and the respective reasons to consider applying biosensors. Biosensors are the most sensitive, specific, rapid, user-friendly tools having the potential to deliver point-of-care diagnostics beyond traditional standards. This review provides a brief introduction to conventional methods used for COVID-19 diagnosis and summarizes their advantages and disadvantages. It also discusses the pathogenesis of COVID-19, potential diagnostic biomarkers, and rapid diagnosis using biosensor technology. The current advancements in biosensing technologies, from academic research to commercial achievements, have been emphasized in recent publications. We covered a wide range of topics, including biomarker detection, viral genomes, viral proteins, immune responses to infection, and other potential proinflammatory biomolecules. Major challenges and prospects for future application in point-of-care settings are also highlighted.

Indexed as

Biosensing TechniquesCOVID-19COVID-19 TestingHumansPandemicsSARS-CoV-2TechnologybiosensorsCOVID-19 biomarkersCOVID-19 diagnosisRT-qPCRSARS-CoV-2

Identifiers

PMID36291035
PMCPMC9599206
OpenAlexW4306920763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.